BioSpace News Archive

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced positive top-line results from the Phase 3 portion of the randomized, double blind, placebo controlled, cross-over, SEAL study evaluating single agent, oral XPOVIO® (selinexor) versus matching placebo in patients with advanced unresectable dedifferentiated liposarcoma.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended September 30, 2020

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced it will release third quarter 2020 financial results on Monday, November 9th, 2020.

Medifast, Inc. (NYSE: MED), the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today reported results for the third quarter ended September 30, 2020.

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2020 financial results on Tuesday, November 10, 2020, after the close of the U.S. financial markets.

Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, at 3:30 p. m. E.T.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will release third quarter 2020 financial results after market close on Monday, November 9, 2020.

DURECT Corporation announced financial results for the three months ended September 30, 2020 and provided a corporate update.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company will release third quarter 2020 financial results on Monday, November 9, 2020 after the close of market.

Hewlett Packard Enterprise (HPE) today announced that Macrogen, a leading precision medicine and biotechnology company, has selected HPE GreenLake to modernize its IT operations, respond to fluctuating demands and deliver the speed, agility and scalability needed to process large-scale medical data analysis on-premises.